NRX Pharmaceuticals, Inc.

NRx Pharmaceuticals, Inc., trading on Nasdaq under the ticker NRXP, is a clinical-stage biopharmaceutical company that reached the public markets through a de-SPAC transaction with Big Rock Partners Acquisition Corp, a blank check company that completed its initial public offering in 2018. Sponsored by Big Rock Partners, the vehicle targeted the healthcare and life sciences sector during its search period. The May 2018 Form 10-Q reflects the SPAC's quarterly reporting obligations as a blank check company ahead of its eventual business combination with NeuroRx, a central nervous system drug developer, which resulted in the combined entity adopting the NRx Pharmaceuticals name. Sign up at SpacDesk for full filing history, sponsor profiles, and deal analytics on NRXP and every SPAC in the market.